Iovance Biotherapeutics
IOVA
131 hedge funds and large institutions have $1.02B invested in Iovance Biotherapeutics in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 20 closing their positions.
238% more call options, than puts
Call options by funds: $5M | Put options by funds: $1.48M
60% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 30
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
4% more funds holding
Funds holding: 126 → 131 (+5)
1.8% more ownership
Funds ownership: 92.86% → 94.66% (+1.8%)
4% less capital invested
Capital invested by funds: $1.07B → $1.02B (-$47.5M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$40.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$20.4M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$19M |
| 4 |
BC
Broadfin Capital
New York
|
+$10.6M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$25.6M |
| 2 |
Millennium Management
New York
|
-$9.26M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.25M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$5.09M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$4.61M |
IOVA Hedge Fund Activity: Q3 2018 in Review
131 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2018, worth a combined $1.02B — down 4.5% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new IOVA positions and 20 closed out — a net gain of 5 holders — while 48 added to existing stakes and 30 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $40.3M. The largest seller was Acuta Capital Partners, cutting an estimated $25.6M.
- 131 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2018, up from 126 in Q2 2018.
- Funds reported $1.02B of Iovance Biotherapeutics stock for Q3 2018, down 4.5% quarter-over-quarter.
- 25 funds opened new Iovance Biotherapeutics positions in Q3 2018 and 20 closed out, a net change of +5 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2018 was Citadel Advisors, an estimated $40.3M added.
- The largest Iovance Biotherapeutics seller in Q3 2018 was Acuta Capital Partners, an estimated $25.6M sold.
Based on aggregated 13F filings for Q3 2018.